123 related articles for article (PubMed ID: 2614181)
1. [A fundamental and clinical investigation of cancer antigen 130 (CA 130) in the field of obstetrics and gynecology].
Inaba N; Okajima Y; Ota Y; Fukazawa I; Yamaguchi T; Sato N; Sudo H; Milanga M; Takamizawa H; Fujii S
Nihon Gan Chiryo Gakkai Shi; 1989 Oct; 24(10):2426-35. PubMed ID: 2614181
[TBL] [Abstract][Full Text] [Related]
2. [Studies of clinical usefulness of new tumor markers of ovarian cancer, CA 54/61 and CA 602--CA 602 assay reagent kit, performance its normal value and correlations with other tumor markers].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
Gan To Kagaku Ryoho; 1992 Oct; 19(12):2085-93. PubMed ID: 1417016
[TBL] [Abstract][Full Text] [Related]
3. Dissociation in serum CA125 concentrations measured by different monoclonal antibodies.
Sakahara H; Kousaka T; Hattori N; Tomida K; Yao Z; Hosono M; Kobayashi H; Shirato M; Endo K; Konishi J
Gynecol Oncol; 1994 Mar; 52(3):301-5. PubMed ID: 7512519
[TBL] [Abstract][Full Text] [Related]
4. The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer.
Devine PL; McGuckin MA; Ramm LE; Harada H; Ward BG
Cancer Biochem Biophys; 1993 Sep; 13(4):221-38. PubMed ID: 8521372
[TBL] [Abstract][Full Text] [Related]
5. [Levels of CA130 in maternal sera and amniotic fluid at various gestational ages].
Kobayashi F; Sagawa N; Okagaki A; Nakamura K; Nonogaki M; Nanbu Y; Ban C; Fujii S; Mori T; Saga T
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):327-32. PubMed ID: 2193069
[TBL] [Abstract][Full Text] [Related]
6. [Levels of circulating tumor-associated glycoprotein (TAG-72) in patients with carcinoma using a novel tumor marker, CA 72-4].
Ohuchi N; Matoba N; Taira Y; Takahashi K; Sakai N; Sato K; Fujita N; Mochizuki F; Nishihira T; Mori S
Gan To Kagaku Ryoho; 1988 Sep; 15(9):2767-72. PubMed ID: 3166366
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801
[TBL] [Abstract][Full Text] [Related]
8. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289
[TBL] [Abstract][Full Text] [Related]
9. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers].
Nozawa S; Udagawa Y; Ito K; Susumu N; Sasaki H; Aoki D
Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of serum CA130 level in women with spontaneous abortion, hydatidiform mole and early normal and tubal pregnancy].
Kobayashi F; Park KR; Yamashita M; Nonogaki M; Hoshino T; Shimada H; Ono Y; Ikeuchi M; Takashima E; Sagawa N
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Nov; 44(11):1427-30. PubMed ID: 1460362
[TBL] [Abstract][Full Text] [Related]
11. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
12. Characterisation and clinical usefulness of CA130 antigen recognised by monoclonal antibodies, 130-22 and 145-9, in ovarian cancers.
Kobayashi H; Ohi H; Fujii T; Terao T
Br J Cancer; 1993 Feb; 67(2):237-43. PubMed ID: 7679280
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
14. Sialyl Lewis-Xi antigen in patients with gynecologic tumors.
Inoue M; Shimizu C; Sasagawa T; Shimizu H; Saito J; Tanizawa O
Obstet Gynecol; 1989 Jan; 73(1):79-83. PubMed ID: 2909045
[TBL] [Abstract][Full Text] [Related]
15. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
16. [Application of monoclonal antibody OC 125 in gynecological oncology].
Wu AR; Wang EY; Wang XX; Jia XH; Li L
Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
[TBL] [Abstract][Full Text] [Related]
17. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
18. [Significance of CA 125 antigen levels in patients with ovarian cancer].
Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
[TBL] [Abstract][Full Text] [Related]
19. [A study of preclinical and clinical usefulness of new tumor markers of ovarian carcinoma, CA 54/61 and CA 602. 1. Evaluation of the diagnostic accuracy of CA 54/61, a study of the normal range of its values and its correlation with other tumor markers].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hasimoto M
Gan To Kagaku Ryoho; 1992 Jun; 19(6):827-35. PubMed ID: 1605661
[TBL] [Abstract][Full Text] [Related]
20. [CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies].
Gang Y; Adachi I; Ohkura H; Yamamoto H; Mizuguchi Y; Abe K
Gan To Kagaku Ryoho; 1985 Dec; 12(12):2379-86. PubMed ID: 3865634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
